These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1237 related items for PubMed ID: 20932310

  • 1. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR, Schellenberg GD, Wang LS, Alzheimer's Disease Neuroimaging Initiative.
    BMC Neurol; 2010 Oct 08; 10():90. PubMed ID: 20932310
    [Abstract] [Full Text] [Related]

  • 2. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.
    Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2011 Jan 04; 76(1):69-79. PubMed ID: 21123754
    [Abstract] [Full Text] [Related]

  • 3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 04; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 4. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
    Cong W, Meng X, Li J, Zhang Q, Chen F, Liu W, Wang Y, Cheng S, Yao X, Yan J, Kim S, Saykin AJ, Liang H, Shen L, Alzheimer’s Disease Neuroimaging Initiative.
    BMC Genomics; 2017 May 30; 18(1):421. PubMed ID: 28558704
    [Abstract] [Full Text] [Related]

  • 5. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
    Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.
    PLoS One; 2013 May 30; 8(4):e59676. PubMed ID: 23573206
    [Abstract] [Full Text] [Related]

  • 6. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.
    Maxwell TJ, Corcoran C, Del-Aguila JL, Budde JP, Deming Y, Cruchaga C, Goate AM, Kauwe JSK, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Res Ther; 2018 Aug 28; 10(1):86. PubMed ID: 30153862
    [Abstract] [Full Text] [Related]

  • 7. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.
    Dement Geriatr Cogn Disord; 2009 Aug 28; 27(5):458-64. PubMed ID: 19420940
    [Abstract] [Full Text] [Related]

  • 8. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
    Sun Y, Bresell A, Rantalainen M, Höglund K, Lebouvier T, Salter H, Alzheimer Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2015 Aug 28; 45(4):1061-76. PubMed ID: 25720397
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 10. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.
    Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen J, Struyfs H, Van Dongen J, Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP, Van Broeckhoven C, BELNEU consortium.
    Alzheimers Dement; 2015 Dec 01; 11(12):1452-1460. PubMed ID: 26086184
    [Abstract] [Full Text] [Related]

  • 11. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C, Alzheimer's Neuroimaging Initiative.
    Neuroimage Clin; 2014 Dec 01; 4():164-73. PubMed ID: 24371799
    [Abstract] [Full Text] [Related]

  • 12. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.
    Acta Neuropathol; 2014 May 01; 127(5):633-43. PubMed ID: 24633805
    [Abstract] [Full Text] [Related]

  • 13. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.
    BMC Neurol; 2015 Apr 01; 15():51. PubMed ID: 25880550
    [Abstract] [Full Text] [Related]

  • 14. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Ramos de Matos M, Ferreira C, Herukka SK, Soininen H, Janeiro A, Santana I, Baldeiras I, Almeida MR, Lleó A, Dols-Icardo O, Alcolea D, Benussi L, Binetti G, Paterlini A, Ghidoni R, Nacmias B, Meulenbroek O, van Waalwijk van Doorn LJC, Kuiperi HBJ, Hausner L, Waldemar G, Simonsen AH, Tsolaki M, Gkatzima O, Resende de Oliveira C, Verbeek MM, Clarimon J, Hiltunen M, de Mendonça A, Martins M.
    J Alzheimers Dis; 2018 Apr 01; 66(2):639-652. PubMed ID: 30320580
    [Abstract] [Full Text] [Related]

  • 15. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.
    Arch Neurol; 1998 Jul 01; 55(7):937-45. PubMed ID: 9678311
    [Abstract] [Full Text] [Related]

  • 16. Association Between Common Variants of APOE, ABCA7, A2M, BACE1, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Data from the PUMCH Dementia Cohort.
    Dong L, Mao C, Liu C, Li J, Huang X, Wang J, Lei D, Chu S, Sha L, Xu Q, Peng B, Cui L, Gao J.
    J Alzheimers Dis; 2022 Jul 01; 85(4):1511-1518. PubMed ID: 34958020
    [Abstract] [Full Text] [Related]

  • 17. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y, Tan L, Wang HF, Liu Y, Hao XK, Tan CC, Jiang T, Liu B, Zhang DQ, Yu JT, Alzheimer’s Disease Neuroimaging Initiative.
    Mol Neurobiol; 2016 Sep 01; 53(7):4539-47. PubMed ID: 26298664
    [Abstract] [Full Text] [Related]

  • 18. Genome-wide association and interaction studies of CSF T-tau/Aβ42 ratio in ADNI cohort.
    Li J, Zhang Q, Chen F, Meng X, Liu W, Chen D, Yan J, Kim S, Wang L, Feng W, Saykin AJ, Liang H, Shen L, Alzheimer's Disease Neuroimaging Initiative.
    Neurobiol Aging; 2017 Sep 01; 57():247.e1-247.e8. PubMed ID: 28641921
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.